NASDAQ:KYMR Kymera Therapeutics (KYMR) Stock Forecast, Price & News $27.05 -2.35 (-7.99%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$26.00▼$27.3550-Day Range$26.24▼$34.9252-Week Range$13.15▼$39.85Volume2.14 million shsAverage Volume430,063 shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice Target$47.22 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Kymera Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside74.6% Upside$47.22 Price TargetShort InterestBearish21.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.66) to ($3.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.59 out of 5 starsMedical Sector825th out of 983 stocksBiological Products, Except Diagnostic Industry133rd out of 164 stocks 3.3 Analyst's Opinion Consensus RatingKymera Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.22, Kymera Therapeutics has a forecasted upside of 74.6% from its current price of $27.05.Amount of Analyst CoverageKymera Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.28% of the float of Kymera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.Change versus previous monthShort interest in Kymera Therapeutics has recently decreased by 1.98%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKymera Therapeutics does not currently pay a dividend.Dividend GrowthKymera Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KYMR. Previous Next 2.6 News and Social Media Coverage News SentimentKymera Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Kymera Therapeutics this week, compared to 2 articles on an average week.Search Interest8 people have searched for KYMR on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kymera Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.01% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kymera Therapeutics are expected to decrease in the coming year, from ($2.66) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kymera Therapeutics is -9.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kymera Therapeutics is -9.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKymera Therapeutics has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kymera Therapeutics (NASDAQ:KYMR) StockKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More Receive KYMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Stock News HeadlinesJune 1, 2023 | finance.yahoo.comKymera Therapeutics to Participate in Upcoming June Investor ConferenceMay 29, 2023 | finance.yahoo.comInvestors in Kymera Therapeutics (NASDAQ:KYMR) have seen notable returns of 95% over the past yearJune 3, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 22, 2023 | markets.businessinsider.comKymera Appoints Jeremy Chadwick As COOMay 22, 2023 | msn.comKymera Therapeutics appoints COOMay 22, 2023 | finance.yahoo.comKymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating OfficerMay 19, 2023 | finance.yahoo.comKymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253May 18, 2023 | finance.yahoo.comKymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology SymposiumJune 3, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 14, 2023 | seekingalpha.comKymera: More Data NeededMay 12, 2023 | americanbankingnews.comAnalysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $47.22May 10, 2023 | americanbankingnews.comBrokers Set Expectations for Kymera Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:KYMR)May 9, 2023 | finance.yahoo.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call TranscriptMay 8, 2023 | markets.businessinsider.comKymera Therapeutics (KYMR) Gets a Buy from H.C. WainwrightMay 8, 2023 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Upgraded by Raymond James to OutperformMay 5, 2023 | msn.comCredit Suisse Maintains Kymera Therapeutics (KYMR) Neutral RecommendationMay 5, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on Kymera Therapeutics (KYMR)May 5, 2023 | msn.comRaymond James Upgrades Kymera Therapeutics (KYMR)May 5, 2023 | msn.comKymera Therapeutics Surges on New Analyst LoveMay 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Integra Lifesciences (IART) and Kymera Therapeutics (KYMR)May 4, 2023 | finance.yahoo.comKymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue EstimatesMay 4, 2023 | finanznachrichten.deKymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business UpdateMay 4, 2023 | finance.yahoo.comKymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business UpdateMay 3, 2023 | americanbankingnews.comKymera Therapeutics (KYMR) Scheduled to Post Earnings on ThursdayApril 19, 2023 | finance.yahoo.comSome Shareholders Feeling Restless Over Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) P/S RatioApril 11, 2023 | finance.yahoo.comKymera Therapeutics to Report First Quarter 2023 Financial Results on May 4April 8, 2023 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) and Novavax (NASDAQ:NVAX) Financial SurveySee More Headlines KYMR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KYMR Company Calendar Last Earnings5/04/2023Today6/03/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KYMR CUSIPN/A CIK1815442 Webwww.kymeratx.com Phone857-285-5300FaxN/AEmployees141Year FoundedN/APrice Target and Rating Average Stock Price Forecast$47.22 High Stock Price Forecast$85.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside+74.6%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,810,000.00 Net Margins-340.80% Pretax Margin-340.80% Return on Equity-34.15% Return on Assets-26.74% Debt Debt-to-Equity RatioN/A Current Ratio6.65 Quick Ratio6.65 Sales & Book Value Annual Sales$46.83 million Price / Sales31.95 Cash FlowN/A Price / Cash FlowN/A Book Value$8.35 per share Price / Book3.24Miscellaneous Outstanding Shares55,310,000Free Float45,900,000Market Cap$1.50 billion OptionableNot Optionable Beta1.72 Key ExecutivesDr. Bruce L. Booth D.Phil. (Age 49)DPHIL, Ph.D., Co-Founder & Chairman Comp: $73kDr. Nello Mainolfi M.D. (Age 44)Ph.D., Co-Founder, Pres, CEO & Director Comp: $940.11kMr. Bruce N. Jacobs CFAChief Financial OfficerDr. Jared A. Gollob M.D. (Age 58)Chief Medical Officer Comp: $676.75kMs. Elaine CaugheyChief Bus. OfficerKevin DushneySr. VP of IT & OperationsMr. Michael J. Todisco (Age 58)VP of Accounting & Fin. Mr. Vijay Sabesan (Age 51)Sr. VP of Technical Operations Ms. Melissa BrodyVP of Bus. Devel.Ms. Karen WeisbachVP of People & CultureMore ExecutivesKey CompetitorsVericelNASDAQ:VCELRecursion PharmaceuticalsNASDAQ:RXRXBioCryst PharmaceuticalsNASDAQ:BCRXSpringWorks TherapeuticsNASDAQ:SWTXPrime MedicineNYSE:PRMEView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,121 shares on 5/26/2023Ownership: 0.015%Ameriprise Financial Inc.Bought 7,470 shares on 5/22/2023Ownership: 0.014%JPMorgan Chase & Co.Bought 15,443 shares on 5/18/2023Ownership: 1.025%New York State Common Retirement FundSold 6,147 shares on 5/18/2023Ownership: 0.038%Gilder Gagnon Howe & Co. LLCSold 690 shares on 5/16/2023Ownership: 0.162%View All Insider TransactionsView All Institutional Transactions KYMR Stock - Frequently Asked Questions Should I buy or sell Kymera Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KYMR shares. View KYMR analyst ratings or view top-rated stocks. What is Kymera Therapeutics' stock price forecast for 2023? 8 equities research analysts have issued twelve-month target prices for Kymera Therapeutics' shares. Their KYMR share price forecasts range from $31.00 to $85.00. On average, they anticipate the company's stock price to reach $47.22 in the next year. This suggests a possible upside of 74.6% from the stock's current price. View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts. How have KYMR shares performed in 2023? Kymera Therapeutics' stock was trading at $24.96 at the beginning of the year. Since then, KYMR stock has increased by 8.4% and is now trading at $27.05. View the best growth stocks for 2023 here. When is Kymera Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our KYMR earnings forecast. How were Kymera Therapeutics' earnings last quarter? Kymera Therapeutics, Inc. (NASDAQ:KYMR) issued its earnings results on Thursday, May, 4th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.01. The firm had revenue of $9.47 million for the quarter, compared to analyst estimates of $14.15 million. Kymera Therapeutics had a negative net margin of 340.80% and a negative trailing twelve-month return on equity of 34.15%. The company's quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm earned ($0.71) earnings per share. What ETFs hold Kymera Therapeutics' stock? ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Simplify Propel Opportunities ETF (SURI), Principal Healthcare Innovators ETF (BTEC), Harbor Disruptive Innovation ETF (INNO) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Kymera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE). When did Kymera Therapeutics IPO? (KYMR) raised $126 million in an initial public offering on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO. What is Kymera Therapeutics' stock symbol? Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR." Who are Kymera Therapeutics' major shareholders? Kymera Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (10.59%), BVF Inc. IL (8.57%), Price T Rowe Associates Inc. MD (8.44%), Wellington Management Group LLP (7.76%), Avoro Capital Advisors LLC (6.97%) and BlackRock Inc. (6.02%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas. View institutional ownership trends. How do I buy shares of Kymera Therapeutics? Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kymera Therapeutics' stock price today? One share of KYMR stock can currently be purchased for approximately $27.05. How much money does Kymera Therapeutics make? Kymera Therapeutics (NASDAQ:KYMR) has a market capitalization of $1.50 billion and generates $46.83 million in revenue each year. The company earns $-154,810,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis. How many employees does Kymera Therapeutics have? The company employs 141 workers across the globe. How can I contact Kymera Therapeutics? Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The official website for the company is www.kymeratx.com. The company can be reached via phone at 857-285-5300 or via email at ir@kymeratx.com. This page (NASDAQ:KYMR) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.